Regeneron Pharmaceuticals annual revenue
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Regeneron Pharmaceuticals Revenue Growth & History (REGN)
Regeneron Pharmaceuticals reported $14.34B in revenue for fiscal 2025, an increase of 0.99% from the previous fiscal year.
View full Regeneron Pharmaceuticals company overviewRegeneron Pharmaceuticals annual revenue and growth
| Fiscal year | Period ended | Revenue | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | $14.34B | $140.9M | +0.99% |
| 2024 | 2024-12-31 | $14.20B | $1.08B | +8.27% |
| 2023 | 2023-12-31 | $13.12B | $944.3M | +7.76% |
| 2022 | 2022-12-31 | $12.17B | −$3.90B | −24.26% |
| 2021 | 2021-12-31 | $16.07B | $7.57B | +89.14% |
| 2020 | 2020-12-31 | $8.50B | $1.94B | +29.58% |
| 2019 | 2019-12-31 | $6.56B | $1.41B | +27.44% |
| 2018 | 2018-12-31 | $5.15B | −$726.6M | −12.37% |
| 2017 | 2017-12-31 | $5.87B | $1.01B | +20.82% |
| 2016 | 2016-12-31 | $4.86B | $756.7M | +18.44% |
| 2015 | 2015-12-31 | $4.10B | $1.28B | +45.55% |
| 2014 | 2014-12-31 | $2.82B | $714.8M | +33.96% |
| 2013 | 2013-12-31 | $2.10B | $726.3M | +52.69% |
| 2012 | 2012-12-31 | $1.38B | $932.7M | +209.20% |
| 2011 | 2011-12-31 | $445.8M | −$13.3M | −2.89% |
| 2010 | 2010-12-31 | $459.1M | $79.8M | +21.04% |
| 2009 | 2009-12-31 | $379.3M | $140.8M | +59.05% |
| 2008 | 2008-12-31 | $238.5M | — | — |
Regeneron Pharmaceuticals quarterly revenue
Q2.09
Q3.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Revenue | Change | YoY growth |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $4.29B | $615.1M | +16.73% |
| Q1 2026 | 2026-03-31 | $3.61B | $576.7M | +19.04% |
| Q4 2025 | 2025-12-31 | $3.88B | $95.1M | +2.51% |
| Q3 2025 | 2025-09-30 | $3.75B | $33.6M | +0.90% |
| Q2 2025 | 2025-06-30 | $3.68B | $128.5M | +3.62% |
| Q1 2025 | 2025-03-31 | $3.03B | −$116.3M | −3.70% |
| Q4 2024 | 2024-12-31 | $3.79B | $354.9M | +10.33% |
| Q3 2024 | 2024-09-30 | $3.72B | $358.0M | +10.65% |
| Q2 2024 | 2024-06-30 | $3.55B | $389.0M | +12.32% |
| Q1 2024 | 2024-03-31 | $3.15B | −$17.1M | −0.54% |
| Q4 2023 | 2023-12-31 | $3.43B | $19.9M | +0.58% |
| Q3 2023 | 2023-09-30 | $3.36B | $426.5M | +14.53% |
| Q2 2023 | 2023-06-30 | $3.16B | $300.9M | +10.53% |
| Q1 2023 | 2023-03-31 | $3.16B | $197.0M | +6.64% |
| Q4 2022 | 2022-12-31 | $3.41B | −$1.54B | −31.05% |
| Q3 2022 | 2022-09-30 | $2.94B | −$516.6M | −14.96% |
| Q2 2022 | 2022-06-30 | $2.86B | −$2.28B | −44.40% |
| Q1 2022 | 2022-03-31 | $2.97B | $436.4M | +17.26% |
| Q4 2021 | 2021-12-31 | $4.95B | $2.53B | +104.37% |
| Q3 2021 | 2021-09-30 | $3.45B | $1.16B | +50.51% |
| Q2 2021 | 2021-06-30 | $5.14B | $3.19B | +163.24% |
| Q1 2021 | 2021-03-31 | $2.53B | $700.5M | +38.32% |
| Q4 2020 | 2020-12-31 | $2.42B | $559.4M | +30.02% |
| Q3 2020 | 2020-09-30 | $2.29B | $550.3M | +31.56% |
| Q2 2020 | 2020-06-30 | $1.95B | $374.2M | +23.72% |
| Q1 2020 | 2020-03-31 | $1.83B | $455.6M | +33.19% |
| Q4 2019 | 2019-12-31 | $1.86B | −$64.3M | −3.34% |
| Q3 2019 | 2019-09-30 | $1.74B | $80.2M | +4.82% |
| Q2 2019 | 2019-06-30 | $1.58B | −$30.2M | −1.88% |
| Q1 2019 | 2019-03-31 | $1.37B | −$138.9M | −9.19% |
| Q4 2018 | 2018-12-31 | $1.93B | $345.4M | +21.83% |
| Q3 2018 | 2018-09-30 | $1.66B | $162.8M | +10.85% |
| Q2 2018 | 2018-06-30 | $1.61B | $137.9M | +9.38% |
| Q1 2018 | 2018-03-31 | $1.51B | $192.5M | +14.59% |
| Q4 2017 | 2017-12-31 | $1.58B | $355.6M | +28.98% |
| Q3 2017 | 2017-09-30 | $1.50B | $280.6M | +23.00% |
| Q2 2017 | 2017-06-30 | $1.47B | $257.5M | +21.23% |
| Q1 2017 | 2017-03-31 | $1.32B | $118.2M | +9.84% |
| Q4 2016 | 2016-12-31 | $1.23B | $128.8M | +11.73% |
| Q3 2016 | 2016-09-30 | $1.22B | $82.7M | +7.27% |
| Q2 2016 | 2016-06-30 | $1.21B | $214.0M | +21.43% |
| Q1 2016 | 2016-03-31 | $1.20B | $331.2M | +38.09% |
| Q4 2015 | 2015-12-31 | $1.10B | $295.7M | +36.86% |
| Q3 2015 | 2015-09-30 | $1.14B | $411.6M | +56.72% |
| Q2 2015 | 2015-06-30 | $998.6M | $332.9M | +50.01% |
| Q1 2015 | 2015-03-31 | $869.6M | $243.9M | +38.97% |
| Q4 2014 | 2014-12-31 | $802.3M | $191.9M | +31.44% |
| Q3 2014 | 2014-09-30 | $725.8M | $128.8M | +21.57% |
| Q2 2014 | 2014-06-30 | $665.7M | $208.1M | +45.46% |
| Q1 2014 | 2014-03-31 | $625.7M | $186.1M | +42.32% |
| Q4 2013 | 2013-12-31 | $610.4M | $195.8M | +47.23% |
| Q3 2013 | 2013-09-30 | $597.0M | $169.3M | +39.59% |
| Q2 2013 | 2013-06-30 | $457.6M | $153.2M | +50.34% |
| Q1 2013 | 2013-03-31 | $439.7M | $207.9M | +89.68% |
| Q4 2012 | 2012-12-31 | $414.6M | $291.6M | +237.14% |
| Q3 2012 | 2012-09-30 | $427.7M | $324.9M | +315.90% |
| Q2 2012 | 2012-06-30 | $304.4M | $196.6M | +182.35% |
| Q1 2012 | 2012-03-31 | $231.8M | $119.6M | +106.58% |
| Q4 2011 | 2011-12-31 | $123.0M | −$10.7M | −8.00% |
| Q3 2011 | 2011-09-30 | $102.8M | −$3.1M | −2.97% |
| Q2 2011 | 2011-06-30 | $107.8M | −$8.1M | −6.97% |
| Q1 2011 | 2011-03-31 | $112.2M | $8.7M | +8.37% |
| Q4 2010 | 2010-12-31 | $133.7M | — | — |
| Q3 2010 | 2010-09-30 | $106.0M | −$11.5M | −9.77% |
| Q2 2010 | 2010-06-30 | $115.9M | $25.9M | +28.72% |
| Q1 2010 | 2010-03-31 | $103.5M | — | — |
| Q3 2009 | 2009-09-30 | $117.5M | — | — |
| Q2 2009 | 2009-06-30 | $90.0M | — | — |
Regeneron Pharmaceuticals revenue growth trends
Over the last five reported fiscal years, revenue grew from $8.50B to $14.34B, a compound annual growth rate of 11.04%. Regeneron Pharmaceuticals's latest reported quarter, Q2 2026, generated $4.29B in revenue, an increase of 16.73% year over year.
About the data
What revenue means
Revenue is the top-line amount a company reports from selling goods and services before expenses are deducted. Fiscal periods can differ from calendar years, so each table includes the exact period end date.
Financial data
Standardized company financials
TickerStat standardizes company financial facts for consistent comparison. Derived growth rates use the displayed values and are not guidance or forecasts.
Review Regeneron Pharmaceuticals source filings ↗